Nasdaq-listed Anixa Biosciences board approves purchase of Bitcoin as reserve asset
Golden Finance reported that the board of directors of Nasdaq-listed Anixa Biosciences has approved the purchase of Bitcoin as a reserve asset. The company also reiterated its ongoing stock repurchase plan. The company's CEO Amit Kumar said that the decision on Bitcoin is another way of prudent financial management to achieve higher shareholder value. It is reported that Anixa Biosciences is a biotechnology company focused on the treatment and prevention of cancer.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Goolsbee: The Federal Reserve should not consider government financing costs when making policy decisions
Machi Big Brother deposits approximately $200,000 into Hyperliquid to "top up" his ETH long position
USDC Treasury minted an additional 85 million USDC on the Solana chain
